Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

Pfiz­er is drop­ping $5.4 bil­lion to ac­quire Glob­al Blood Ther­a­peu­tics.

Just ahead of the week­end, word got out that Pfiz­er was close to clinch­ing a $5 bil­lion buy­out — al­beit with oth­er po­ten­tial buy­ers still at the ta­ble. The phar­ma gi­ant, flush with cash from Covid-19 vac­cine sales, ap­par­ent­ly got out on top.

The deal im­me­di­ate­ly swells Pfiz­er’s pre­vi­ous­ly tiny sick­le cell dis­ease port­fo­lio from just a Phase I pro­gram to one with an ap­proved drug, Oxbry­ta, plus a whole pipeline that, if all ap­proved, the com­pa­ny be­lieves could make for a $3 bil­lion fran­chise at peak.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER